Publications scientifiques

Téléchargez nos documents

2022 Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPα immune checkpoint inhibitor BI 765063 in patients with advanced solid tumors : AACR 2022 (American Association Cancer Research)
2021 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 (Tedopi®) vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial: SITC (Society for Immunotherapy of Cancer) 2021
2021 Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor: ESMO (European Society for Medical Oncology) 2021
2021 Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology: SITC (Society for Immunotherapy of Cancer) 2021
2021 Long-term anti-tumor preclinical efficacy of an optimized anti-PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity: SITC (Society for Immunotherapy of Cancer) 2021
2021 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of Phase 3 Atalante-1 randomised trial: ESMO 2021
2021 Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO 2016
2021 Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: results of monotherapy dose escalation in Phase 1 study in patients with advanced solid tumors: ASCO 2021
2021 Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis and metastasis: AACR 2021
2021 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation: AACR 2021
2021 BICKI®IL-7, optimized bifunctional anti PD-1/IL-7 drug, with good PK profile and preclinical anti-tumor efficacy: AACR 2021
2021 Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution: Science Advances
2020 Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance: Journal of Clinical Investigation
2020 Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine: BioRxiv
2019 Early signs of activity of Tedopi (OSE2101), a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors (ICI) Atalante 1 study trial: AACR 2019
2018 Full antagonist of the IL-7 receptor suppresses chronic inflammation in non-human primate models by controlling antigen-specific memory T cells: Cell Stress
2018 SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid‐derived suppressor cells: American Journal of Transplantation
2018 Vaccines as an Integral Component of Cancer Immunotherapy: JAMA
1 2 3 4

Inscrivez-vous à notre newsletter